Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$26.90 -0.91%

-$0.33 today

Market cap
$1.37B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.04M

Average 0.08M

NBTX Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Nanobiotix S.A.NASDAQ: NBTX

Cost of Revenue · Q4 FY2025 · quarter ended Dec 2025

Cost of revenue remains negative

Q4 FY2025 cost of revenue was €0, compared with €0 a year earlier.

Context

  • Cost of revenue amounted to 0.0% of revenue in FY2025.
  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
€0— QoQ
Last fiscal yearDec 2025
€0— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cost of Revenue history

EUR · from the income statement

Latest · FY2025
0 EUR
Year-over-year change
—

Cost of Revenue vs competitors

How NBTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Cost of revenue amounts to 0.0% of revenue for NBTX, versus a peer median of 4.3%.
NBTX Competitors
Cost of Revenue for NBTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PBYIPuma Biotechnology, Inc.LTM Mar 2026$58.03M USD-9.7%+1.8%25.5%
IBRXImmunityBio, Inc.LTM Sep 2026$6.07M USD+40.5%—3.3%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$4.44M USD+401.7%—2.0%
KURAKura Oncology, Inc.LTM Mar 2026$3.83M USD+1795.5%—5.3%
TYRATyra Biosciences, Inc.LTM Mar 2026$138K USD+9.5%——
IMMXImmix Biopharma, Inc.LTM Mar 2026$130.77K USD———
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$113K USD+31.4%——
NBTXNanobiotix S.A.FY2025€0 EUR——0.0%
NVCTNuvectis Pharma, Inc.LTM Mar 2026$0 USD———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
CADLCandel Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding NBTX) —+36.0%+1.8%4.3%

Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.65M4.78M36.21M(7.19M)29.64M
Cost of Revenue00000
Gross Profit2.65M4.78M36.21M(7.19M)29.64M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development30.38M32.64M38.4M40.54M23.12M
Selling, General & Admin19.43M17.86M22.05M20.53M20.22M
Operating Expenses55.23M51.48M62.99M61.2M40.46M
Depreciation & Amortization1.56M1.5M551K592K1.5M
EBITDA(45.61M)(44.22M)(23.69M)(67.67M)(12.07M)
EBITDA Margin-1722.9%-925.8%-65.4%941.1%-40.7%
Operating Income(52.58M)(46.7M)(26.78M)(68.39M)(10.82M)
Operating Margin-1986.4%-977.8%-74.0%951.2%-36.5%
Interest Income0256K1.22M2.63M985K
Interest Expense699.49K5.84M7.98M8.09M10.4M
Other Income / Expenses5.58M(10.33M)(12.8M)361K(13.14M)
Income Before Tax(47M)(57.03M)(39.58M)(68.03M)(23.96M)
Pre-Tax Margin-1775.5%-1194.1%-109.3%946.2%-80.8%
Income Tax Expense5K10K120K101K3K
Net Income(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Net Margin-1775.7%-1194.3%-109.6%947.6%-80.8%
EPS (Basic)(1.35)(1.64)(1.08)(1.44)(0.50)
EPS (Diluted)(1.35)(1.64)(1.08)(1.44)(0.50)
Weighted Avg Shares34.73M34.85M36.76M47.27M47.82M
Weighted Avg Shares (Diluted)34.73M34.85M36.93M47.27M47.82M

Nanobiotix S.A.

NASDAQ:NBTX

Intrinsic Alpha fair value

Locked

Current Price

$26.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.